Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina  by Chaitman, Bernard R. et al.
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nti-Ischemic Effects and
ong-Term Survival During Ranolazine
onotherapy in Patients With Chronic Severe Angina
ernard R. Chaitman, MD, FACC,* Sandra L. Skettino, MD,† John O. Parker, MD, FACC,‡
eter Hanley, MD, FACC,§ Jaroslav Meluzin, MD, PHD, Jerzy Kuch, MD, PHD,¶
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arsaw, Poland; Gainesville, Florida; and Research Triangle Park, North Carolina
OBJECTIVES The primary objective of the Monotherapy Assessment of Ranolazine In Stable Angina
(MARISA) trial was to determine the dose-response relationship of ranolazine, a potentially
new anti-anginal compound, on symptom-limited exercise duration.
BACKGROUND Fatty acids rise precipitously in response to stress, including acute myocardial ischemia.
Ranolazine is believed to partially inhibit fatty acid oxidation, shift metabolism toward
carbohydrate oxidation, and increase the efficiency of oxygen use.
METHODS Patients (n  191) with angina-limited exercise discontinued anti-anginal medications and
were randomized into a double-blind four-period crossover study of sustained-release
ranolazine 500, 1,000, or 1,500 mg, or placebo, each administered twice daily for one week.
Exercise testing was performed at the end of each treatment during both trough and peak
ranolazine plasma concentrations.
RESULTS Exercise duration at trough increased with ranolazine 500, 1,000, and 1,500 mg twice daily
by 94, 103, and 116 s, respectively, all greater (p  0.005) than the 70-s increase on placebo.
Dose-related increases in exercise duration at peak and in times to 1 mm ST-segment
depression at trough and peak and to angina at trough and peak were also demonstrated (all
p  0.005). Ranolazine had negligible effects on heart rate and blood pressure. One year
survival rate combining data from the MARISA trial and its open-label follow-on study was
96.3  1.7%.
CONCLUSIONS In chronic angina patients, ranolazine monotherapy was well tolerated and increased exercise
performance throughout its dosing interval at all doses studied without clinically meaningful
hemodynamic effects. One-year survival was not lower than expected in this high-risk patient
population. This metabolic approach to treating myocardial ischemia may offer a new
therapeutic option for chronic angina patients. (J Am Coll Cardiol 2004;43:1375–82)
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tcute myocardial ischemia is characterized by a number of
aladaptive metabolic responses that amplify the direct
eleterious effects of an imbalance between oxygen supply
nd demand. Fatty acid levels rise abruptly, promoting their
yocardial uptake and oxidation. Because more oxygen is
equired to phosphorylate a given amount of adenosine
riphosphate during fatty acid oxidation than during carbo-
ydrate oxidation, this abrupt elevation in circulating free
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tudy sponsor CV Therapeutics and hold company stocks; Dr. Parker: consultant to
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nvestigators on behalf of study sponsor CV Therapeutics.
Manuscript received September 16, 2003; revised manuscript received November 6,
s003, accepted November 13, 2003.atty acids causes an inefficient use of the already limited
xygen supply. In addition, elevated free fatty acids directly
uppress the myocardial uptake and oxidation of more
xygen-efficient carbohydrate fuels such as glucose, lactate,
nd pyruvate, further exacerbating both the oxygen wasting
nd the accumulation of lactate (Fig. 1A) (1).
Ranolazine, an investigational treatment for angina, is
ot a beta-adrenergic receptor blocker, a calcium channel
ntagonist, or a vasodilator. Rather, ranolazine appears to
hift adenosine triphosphate production away from fatty
cid oxidation in favor of more oxygen-efficient carbohy-
rate oxidation (2) (Fig. 1B), especially when free fatty acids
re elevated, as they are during ischemia (3). This shift in
ubstrate selection should reduce the oxygen required to
upport any level of cardiac work. Furthermore, preferential
se of the available oxygen for carbohydrate metabolism
uring ischemia should maintain the coupling of glycolysis
o pyruvate oxidation, minimizing lactate accumulation (and
ubsequent tissue acidosis) (Fig. 1B) (1).
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oxidation in the Krebs cycle is improved so that lactate accumulation is
diminished.
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Ranolazine Monotherapy of Chronic Angina April 21, 2004:1375–82Ranolazine has demonstrated anti-ischemic activity in a
ariety of in vitro and in vivo systems (2,4–13). In earlier
linical studies, an immediate-release formulation of rano-
azine, in combination with other anti-anginal medications,
ncreased exercise treadmill test (ETT) performance in
atients with chronic angina without decreases in blood
ressure (BP) or heart rate (HR), both at rest and at peak
xercise, but only at times associated with peak ranolazine
lasma concentrations (1 to 3 h after dosing) (14,15). None
f the earlier studies evaluated the drug prospectively as
onotherapy for angina, and none reported long-term
ollow-up data. Subsequently, a sustained-release (SR) for-
ulation was developed to maintain effective plasma con-
entrations with twice daily administration.
The Monotherapy Assessment of Ranolazine In Stable
ngina (MARISA) trial—a multi-national, randomized,
ouble-blind, placebo-controlled study—is the first trial of
anolazine SR monotherapy in patients with chronic angina.
ts purpose was to assess the tolerability of three doses of
anolazine SR compared to placebo and their effects on
readmill exercise performance and to provide long-term
urvival data in patients that completed the trial.
ETHODS
atient selection. Patients were at least 21 years of age,
ad well-documented coronary artery disease, and had at
east a three-month history of effort angina responding to
eta-blockers, calcium channel blockers, and/or long-acting
itrates. All patients discontinued anti-anginal treatment
uring the study (except sublingual nitroglycerin as needed)
nd provided written informed consent. Key exclusion
riteria were: conditions that might compromise electrocar-
iogram (ECG) or ETT interpretation (e.g., treatment with
igoxin, 1 mm ST-segment depression at rest, left bundle
ranch block, pacemaker rhythm); New York Heart Asso-
iation functional class III or IV congestive heart failure;
nstable angina, myocardial infarction, or any coronary
evascularization procedure within two months of enroll-
ent; corrected QT interval (QTc) 500 ms or any
edication known to prolong the QTc interval; or require-
ent for medication or food known to affect metabolism by
ytochrome P450 3A4. Appropriate precautions were taken
Abbreviations and Acronyms
ANOVA  analysis of variance
BP  blood pressure
CARISA  Combination Assessment of Ranolazine In
Stable Angina trial
ECG  electrocardiogram/electrocardiographic
ETT  exercise treadmill test
HR  heart rate
MARISA  Monotherapy Assessment of Ranolazine In
Stable Angina trial
SR  sustained releaseor women of childbearing potential.igure 1. Regulation of carbohydrate metabolism by fatty acid oxida-
ion. Predominating pathways are represented by open arrows; in-
ibited pathways are represented by dotted arrows. (A) When fatty
cid levels are elevated, the end products of beta-oxidation reduce the
ctivity of pyruvate dehydrogenase, the enzyme that mediates the
onversion of pyruvate to acetyl CoA and permits its entry into the
rebs cycle. As a result, oxygen-wasting fatty acid oxidation predom-
nates, pyruvate oxidation is inhibited, and lactate accumulates with
eleterious consequences. (B) Inhibiting fatty acid oxidation with
anolazine should relieve the inhibition of pyruvate dehydrogenase,
romoting oxidation of glucose and lactate, which phosphorylates a
iven amount of ATP using less oxygen than fatty acid oxidation. In
ddition, the coupling of pyruvate formation via glycolysis to pyruvate
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April 21, 2004:1375–82 Ranolazine Monotherapy of Chronic AnginaAfter discontinuation of all prophylactic anti-anginal
edications, eligible patients entered a single-blind
lacebo-treatment qualifying phase during which they had
wo modified Bruce ETTs (16) conducted one week apart.
atients were randomized into the double-blind phase of
he study if they developed exercise-limiting angina and 1
m horizontal or downsloping ST-segment depression
elow the isoelectric line between 3 and 9 min during each
ualifying ETT and the difference in exercise duration
etween the two tests did not exceed 20% of the longer test
r 1 min. In patients with permitted baseline ST-segment
epression at rest (1 mm), qualifying ST-segment depres-
ion was defined as additional ST-segment depression 1
m below the resting value.
tudy design and procedures. The protocol was approved
y the institutional review board at each participating
nstitution and written informed consent was obtained from
ach patient. Randomized patients received double-blind
reatment with ranolazine SR at doses of 500, 1,000, and
,500 mg or placebo (CV Therapeutics, Palo Alto, Califor-
ia), each administered twice daily for one week, according
o a four-period, balanced Latin Square crossover design. At
he end of each treatment period, ETTs were performed at
imes approximating peak and trough ranolazine plasma
oncentrations: 4 and 12 h after dosing (hereafter referred to
s peak and trough, respectively). Sublingual nitroglycerin
as not permitted for at least 60 min before testing.
Standing HR and systolic BP were measured at rest and
t maximal exercise during each trough and peak ETT. A
upine 12-lead ECG was obtained before each ETT and
tanding ECGs were monitored throughout ETT testing.
core ECG laboratory (St. Louis University, St. Louis,
issouri) interpreted all rest and exercise ECGs blinded to
reatment assignment. All rest ECGs were classified using
he Minnesota code. All exercise ECGs were analyzed using
ustomized software as previously described (17).
Blood samples for analysis of plasma ranolazine concen-
rations were collected before each ETT during double-
lind treatment. Clinical evaluations and adverse event
onitoring occurred throughout the study. Laboratory tests
ere performed at screening and the final visit.
Of 191 patients randomized in the MARISA trial, 168
88.0%) completed all four cross-over periods. Of these, 143
85.1%) patients agreed to participate in an open-label study
onsisting of a 1- to 6-week titration phase starting with
anolazine monotherapy at 750 mg twice daily, escalating to
,000 mg twice daily as needed based on angina relief, and
hen addition of other anti-anginal medication if necessary.
tatistical analysis. The primary efficacy end point of the
tudy was total exercise duration at trough. Other efficacy
nd points included time to onset of angina and time to
mm ST-segment depression at trough, and the same three
TT end points at peak. The primary efficacy analysis
opulation included patients who completed at least three of
heir four double-blind study periods. Randomized patients eho received at least one dose of study drug were included
n the safety evaluation.
For the primary efficacy analysis, adjustment for multiple
omparisons of each ranolazine dose to placebo was ad-
ressed by a three-stage step-down procedure. This was
ased on closed testing and intersection union principles
nd maintained the experiment-wise type I error rate at 0.05
18,19). All p values reflect comparisons versus placebo.
Treadmill parameters, ECG intervals, and hemodynamic
arameters were assessed using standard analysis of variance
ANOVA) models for a crossover study design with treat-
ent, period, pooled site, and patient within pooled site as
actors. Estimates of the treatment differences (i.e., ranola-
ine vs. placebo) for each ranolazine dose and the associated
tatistical significance were obtained. The balanced Latin
quare study design allowed a secondary analysis to be
onducted in the context of an ANOVA to determine the
resence or absence of a first-order carry-over effect. The
cNemar’s test was used for the analysis of dichotomous
aired data (e.g., reason for stopping the ETT categorized
s angina or not angina). All other data were summarized
escriptively. Treatment means and differences are least-
quares means from the ANOVA model unless otherwise
oted.
A survival curve was prepared using Kaplan-Meier esti-
ates (20). All patients who received at least one dose of
anolazine were included on an intent-to-treat basis. Pa-
ients were censored at one day after their last treatment
ith ranolazine.
ESULTS
he study began in December 1997 and ended in May
999; long-term follow-up is reported through October 15,
001. A total of 191 patients were enrolled at 52 investiga-
ional sites in four countries (U.S., Czech Republic, Poland,
nd Canada) and received at least one dose of double-blind
tudy medication.
Patient characteristics are summarized in Table 1. Of the
91 randomized patients, all received at least one dose of
ouble-blind medication and were evaluated for safety; 175
91.6%) completed three of the four treatment periods and
ere thus included in the primary efficacy analysis popula-
ion as defined prospectively in the protocol. Compliance,
efined as receiving 67% to 125% of study drug, was
bserved in more than 96% of patients during each treat-
ent period.
Twenty-three patients (12%) discontinued the study be-
ore completing all treatment periods: 15 patients (7.9%) for
dverse events, 4 patients (2.1%) by elective withdrawal, 2
atients (1.0%) for other reasons, 1 patient (1%) because
f death, and 1 patient (1%) because of inappropriate
nrollment.
xercise treadmill tests. Compared to placebo, treatment
ith ranolazine at all doses significantly improved totalxercise duration, time to angina, and time to 1 mm
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Ranolazine Monotherapy of Chronic Angina April 21, 2004:1375–82T-segment depression at both the trough and peak time
oints (Table 2, Fig. 2A). A dose-response relationship for
ll three exercise parameters was apparent.
At trough, 71.8%, 67.2%, 60.3%, and 56.8% of patients
eceiving placebo or ranolazine 500, 1,000, or 1,500 mg,
espectively, stopped exercising because of angina. At peak,
hese percentages were 70.3%, 64.9%, 62.6%, and 52.4%,
espectively. The differences in proportions versus placebo
able 1. Patient Characteristics (n  191)
Parameter
All
Enrolled
Patients
en 73.3%
ge (yrs)
Mean (SD) 64.3  9.4
Range 39–85
aucasian 91.1%
ntianginal drugs discontinued before randomization
Long-acting nitrates 58.1%
Beta-adrenergic receptor antagonists 56.5%
Calcium-channel antagonists 38.2%
One of the above 37.2%
Two of the above 47.6%
All three of the above 6.8%
aseline electrocardiographic findings by (Minnesota Code)
Pathologic Q waves 15.7%
Major ST-T abnormalities (without pathologic Q waves) 14.7%
Minor ST-T abnormalities (without pathologic Q waves) 27.2%
No pathologic Q waves or significant ST-T
abnormalities
42.4%
rior myocardial infarction 52.3%
ongestive heart failure (class I/II) 16.8%
rior coronary artery bypass grafting 27.7%
rior coronary angioplasty 32.5%
ypertension 64.4%
iabetes 24.1%
ntermittent claudication 9.4%
hronic obstructive pulmonary disease/asthma 6.8%
able 2. Mean Exercise Treadmill Test Parameters in Seconds* (
Parameter
Placebo
(Duration or
Time)
Trough Peak
xercise duration (s)
Mean 505.7 501.7
Standard error 5.7 5.2
p Value — —
ime to angina (s)
Mean 407.3 416.3
Standard error 6.8 6.1
p Value — —
ime to 1 mm ST-segment depression
Mean 443.4 436.4
Standard error 5.7 5.9
p Value — —
Mean durations or times receiving placebo, differences from placebo, and standard e
or treatment, period, pooled site, and patient within pooled site; associated p values a
t trough and 442.7 s at peak.b.i.d.  twice daily.ere significant for the 1,000 and 1,500 mg ranolazine
reatments at both trough and peak (all p  0.04).
For all treadmill efficacy times, the first-order carryover
ffect assessed via ANOVA models was not significant at
he 0.1 level, indicating that there was no significant effect
f the preceding treatment on the effect of the subsequent
reatment.
emodynamic changes at rest and maximal exercise. No
linically significant changes in rest or exercise HRs or BPs
ere observed. The 500 mg dose had no effect on any of
hese values. At peak, ranolazine 1,500 mg twice daily
ecreased resting HR by 3 beats/min (p  0.001), resting
ystolic BP by 3 mm Hg (p  0.05), and exercise systolic
P by7 mm Hg (p 0.001). At trough, ranolazine 1,500
g twice daily decreased resting HR by 3 beats/min (p 
.001) and exercise systolic BP by 6 mm Hg (p  0.001).
afety. ADVERSE EVENTS. The overall adverse event rate
or the 500 mg dose was similar to that for placebo (15.6%
n placebo vs. 16.0% on ranolazine 500 mg) (Table 3);
dverse events increased with higher doses. Specific dose-
elated adverse events included dizziness, nausea, asthenia,
nd constipation; these occurred substantially more fre-
uently on 1,500 mg twice daily than on 1,000 mg twice
aily. Early withdrawal from the study because of adverse
vents also occurred predominantly during dosing with
,500 mg twice daily (11 patients) compared with two, one,
nd one patient during treatment with placebo, ranolazine
00 mg twice daily, and ranolazine 1,000 mg twice daily,
espectively.
LECTROCARDIOGRAPHIC FINDINGS. Minor dose-related
CG changes were observed with ranolazine treatment.
ean differences in QTc interval (Bazett correction) versus
lacebo were 6, 7, and 11 ms at trough and 5, 6, and 14 ms
t peak for the ranolazine 500, 1,000, and 1,500 mg twice
175)
Ranolazine Treatment
00 mg b.i.d. 1,000 mg b.i.d. 1,500 mg b.i.d.
(Difference From Placebo)
gh Peak Trough Peak Trough Peak
29.3 33.7 50.1 45.9 55.5
7.2 8.0 7.2 8.0 7.3
03  0.001  0.001  0.001  0.001  0.001
35.5 45.9 56.4 59.6 68.5
8.5 9.5 8.5 9.6 8.6
05  0.001  0.001  0.001  0.001  0.001
38.8 44.5 55.6 64.6 69.0
8.2 8.1 8.2 8.2 8.4
01  0.001  0.001  0.001  0.001  0.001
re least squares mean estimates from the analysis of variance model including effects
rted. The unadjusted mean baseline exercise duration for the population was 440.1 sn 
5
Trou
23.8
7.9
0.0
27.0
9.5
0.0
27.6
8.1
 0.0
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April 21, 2004:1375–82 Ranolazine Monotherapy of Chronic Anginaaily treatments, respectively. No patient discontinued the
tudy because of QTc prolongation, prospectively defined as
n increase of30% from baseline to a value500 ms. The
igure 2. Symptom-limited exercise duration: dose and plasma concentra-
ion relationships. (A) Exercise duration versus ranolazine dose. Data are
hown at trough (solid bars, primary end point) and peak (lined bars).
tatistically significant increases were observed on each ranolazine dose
ersus placebo (*p  0.005 vs. placebo; **p  0.001 vs. placebo). A
ose-response relationship was evident with greater increases at peak than
t trough. Similar data were observed for time to onset of angina and time
o 1 mm ST-segment depression (Table 2). (B) Exercise duration versus
anolazine plasma concentration. Mean exercise duration increases with
ean plasma ranolazine concentrations. From left to right, values on each
reatment at trough and peak, respectively, are represented by diamonds
placebo), squares (500 mg twice daily), circles (1,000 mg twice daily), and
riangles (1,500 mg twice daily). Dotted lines represent the 95% confi-
ence intervals around the fitted curve.T dispersion was unaffected by any dose of ranolazine.
b.i.d.  twice daily.LINICAL LABORATORY RESULTS. Clinically significantly
igh eosinophil counts occurred in 6 of 169 patients with
nd-of-study data (3.6%). Counts in these patients ranged
rom 2.9% to 8.6% at baseline and increased from 13.2% to
3.0% at end study. All counts returned to normal during a
ollow-on study in which patients continued on open-label
anolazine.
anolazine plasma concentrations. There was a clear
onotonic relationship between mean ranolazine plasma
oncentrations and mean exercise durations (Fig. 2B). The
ncrease in exercise duration appears to plateau at the higher
anolazine concentrations.
ubgroup analyses. The effect of ranolazine in diabetic
ubjects was compared to the nondiabetic cohort to deter-
ine if the metabolic abnormalities associated with this
ondition had an impact on the beneficial increase in total
xercise time observed or were associated with a different
ide-effect profile. Diabetics accounted for 24% of the total
opulation enrolled in the MARISA trial. Total exercise
uration at trough was 498.5  13.9 s, 519.6  13.9 s,
26.0  13.9 s, and 530.4 14.5 s in the diabetic group (n
42) and 503.4  6.3 s, 528.1  6.3 s, 539.1  6.3 s, and
53.8  6.4 s in the nondiabetic group (n  133) for the
lacebo, 500 mg, 1,000 mg, and 1,500 mg twice daily
anolazine doses, respectively. The p value of treatment by
iabetes interaction was 0.77, indicating no statistical evi-
ence of a differential treatment effect by history of diabetes.
he side-effect profile and frequency of adverse events were
imilar in diabetics and nondiabetics, with asthenia, consti-
ation, dizziness, and nausea being the most common side
ffects reported more frequently during treatment with
anolazine.
Similar analyses were conducted by gender, prior history
f heart failure (NYHA functional class I or II), and age
65 and 65 years). As indicated by the non-statistically
ignificant p values of treatment by subgroup interaction,
here was no evidence that the treatment effects of ranola-
ine within any of these particular subgroups were incon-
istent with that observed in the overall population. The
espective p values of treatment by subgroup interaction
ere 0.65, 0.94, and 0.054 for gender, heart failure, and age.Table 3. Most Frequently Occurring Adverse Events, Incidence 3% for Any Treatment*
(n  191)
Adverse Event Placebo
Ranolazine Treatment
500 mg b.i.d. 1,000 mg b.i.d. 1,500 mg b.i.d.
Any adverse event 15.6% 16.0% 21.7% 34.2%
Dizziness 1.1% 1.1% 5.0% 12.3%
Nausea 0 1% 1.1% 8.6%
Asthenia 2.2% 0 1.7% 6.4%
Constipation 0 0 1.7% 4.3%
Angina pectoris 5.0% 5.0% 1.7% 3.2%
Headache 2.2% 1% 1.1% 2.7%
Sweating 0 0 0 2.7%
*Events counted for each treatment during which event was present, even if continued from an earlier period.
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Ranolazine Monotherapy of Chronic Angina April 21, 2004:1375–82ong-term follow-up. Of the 143 patients participating in
he open-label study, 115 (80.4%) and 100 (69.9%) were
till receiving ranolazine at one year and two years after their
rst doses, respectively; the majority (70%) were receiving
,000 mg twice daily. Their one-year and two-year survival
ate on ranolazine (95% confidence interval) were 96.3%
93.0% to 99.5%) and 93.6% (89.3% to 98.0%), respectively
Fig. 3).
ISCUSSION
he abrupt rise in free fatty acid levels during acute
yocardial ischemia (1) and infarction (21) and its delete-
ious consequences (22,23) was first reported more than
hree decades ago but has yet to be fully exploited as a target
or therapeutic intervention. Infusions of glucose, insulin,
nd potassium (intended to promote glucose uptake and
xidation and to reduce oxidation of free fatty acids) have
chieved some success in the treatment of acute myocardial
nfarction (24–28) but are impractical for prophylaxis of
hronic angina.
To date, few available therapies for chronic angina have
een targeted specifically toward normalizing myocardial
etabolism, and these have not achieved widespread use
29,30). Thus, an effective and well-tolerated metabolic
nti-anginal agent remains an attractive therapeutic goal.
irst, metabolic intervention offers the potential to reduce
he lactate accumulation and oxygen wasting associated with
he precipitous ischemic rise in free fatty acids. Second, by
educing the oxygen demand necessary to support a given
evel of cardiac work, a metabolic mechanism might avoid
eductions in BP, HR, or contractile function, effects of
urrently available anti-anginal agents that can be undesir-
ble in some patients. Finally, many patients continue to
igure 3. Survival during long-term ranolazine treatment. Kaplan-Meier
urvival curve including 191 patients who received ranolazine during the
ouble-blind portion of the trial; 143 patients completed the double-blind
tudy and continued on treatment with open-label ranolazine, as described
n the Methods section. The curve was constructed from the first date of
anolazine treatment during the double-blind four-period crossover study,
nd includes a subsequent week of placebo treatment for the 140 patients
ho were not randomized to begin double-blind treatment with placebo.
I  confidence interval.ave angina despite the best current therapy (31) and thus aight benefit from a new agent with a mechanism comple-
entary to those of existing drugs.
During exercise testing of patients with chronic angina,
anolazine, which partially inhibits fatty acid oxidation,
ignificantly increased total exercise duration from 24 to 56 s
ore than placebo at doses of 500 to 1,500 mg twice daily.
he symptoms and ECG evidence of myocardial ischemia
uring exercise testing were similarly delayed or prevented
hroughout the 12-h dosing interval (Table 2). Although
he subgroup analyses contain relatively small numbers of
atients, the beneficial effects on exercise tolerance time was
bserved in diabetics, patients who reported a prior history
f mild heart failure, those over age 65 years, and in men
nd women, and were consistent with the overall study
esults.
These increases in exercise performance are similar to
hose reported for maximal doses of nitrates (32), beta-
lockers (33,34), and calcium channel blockers (33,35,36) in
imilar patients. Comparisons of exercise data across differ-
nt trials, however, should recognize that the increment in
xercise performance versus placebo depends upon an inter-
ction among several trial-specific factors, including the
xercise protocol, the patient population, the uniformity of
dministration of the test, the criteria for a positive ischemic
esponse, and the efficacy of the drug.
For example, Stone et al. (33) studied placebo, propran-
lol, diltiazem, and nifedipine as anti-anginal monothera-
ies titrated to their maximum tolerated doses, each for two
eeks in a crossover trial. At peak, only diltiazem signifi-
antly prolonged exercise duration, by 30 s versus placebo.
xercise durations on nifedipine and propranolol were no
ifferent from placebo in this trial. Increases versus placebo
n time to 1 mm ST-segment depression were 6 s for all
hree drugs; increases in time to angina ranged from 18 to
0 s. Similarly, in the Angioplasty Compared to Medicine
ACME) study, combination therapy allowing all three
ajor anti-anginal classes titrated to their maximum toler-
ted doses increased exercise duration by 30 s from baseline
37). In Randomized Intervention Treatment of Angina-2
RITA-2), a trial comparing coronary angioplasty to med-
cal therapy for angina relief, the average increase in exercise
ime three months after randomization to coronary angio-
lasty was 37 s greater than with medical therapy (38).
inally, long-acting nitrates are mechanistically incapable of
aintaining a continuous anti-anginal effect and must be
ithdrawn daily to restore responsiveness to a subsequent
ose (32). Thus, the increases in exercise duration of 24 to
6 s demonstrated throughout the dosing interval on rano-
azine versus placebo in the current study appear to be
linically useful.
Consistent with the proposed metabolic mechanism that
equires further study, improvements in exercise tolerance
n ranolazine do not appear to be explained by effects on BP
r HR. First, ranolazine 500 mg twice daily significantly
ncreased all three treadmill efficacy variables at both peak
nd trough without any effects on BP or HR. Second,
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oses studied. Finally, the small decreases in exercise systolic
P at the two higher ranolazine doses translated to small
eclines in maximum rate-pressure product; however, in
omparable studies, calcium channel blockers, and in par-
icular, beta-blockers generally cause larger decreases in
ouble product to produce similar or smaller improvements
n exercise performance (33).
Ranolazine also appeared to be generally well tolerated by
he chronic angina patients in this trial, particularly at the
ower two doses. Fewer than 8% of patients discontinued
anolazine because of adverse effects, and almost three-
uarters of these withdrawals occurred at the 1,500 mg dose.
ose-related complaints of dizziness, nausea, asthenia, and
onstipation were also considerably more common on the
,500 mg dose than on the lower two doses, suggesting that
or most patients, the optimum dose for both efficacy and
olerability can be achieved by starting with 500 mg twice
aily and titrating upwards to 750 mg twice daily and 1,000
g twice daily as needed to control angina. A crossover
esign with relatively brief treatment periods (one week
ach) was employed in this study to allow a definitive,
lacebo-controlled assessment of the anti-anginal efficacy of
anolazine monotherapy while minimizing the exposure of
hese severely limited patients to placebo-only treatment.
he interpretation of crossover studies may be confounded
y carryover effects. In this study, however, first-order
arryover effects were not statistically significant at the 0.1
evel for each of the three major treadmill exercise variables
t both trough and peak.
Studies with longer-term follow-up in a broader popula-
ion of angina patients will better assess the continued
fficacy, tolerability, and safety of the drug. In particular, the
elative lack of hemodynamic effects and novel mechanisms
f ranolazine may render it especially useful for concomitant
dministration with other anti-anginal therapies. A
lacebo-controlled trial of 12 weeks’ treatment with rano-
azine at 750 or 1,000 mg twice daily, in combination with
beta-blocker or a calcium channel blocker (the CARISA
rial), also reported significant increases in treadmill exercise
erformance in association with significant decreases in
ngina frequency and nitroglycerin consumption (39). In
he CARISA trial, there was no statistical evidence of a
ifferential treatment effect among patients receiving differ-
nt background therapies (treatment-by-background inter-
ction p  0.63).
A total of 143 patients in the MARISA trial participated
n the open-label long-term ranolazine study. The average
uke treadmill score at entry was 13.7  0.2, a score
onsistent with a prognostic high-risk patient cohort (40).
lthough the 3.7% first-year mortality rate observed on
anolazine compares favorably with the approximate 9%
nnual rate reported in historical controls with a Duke
readmill score worse than10 (40), comparative treatment
ifferences on survival would need to be addressed by
andomized clinical trialsIn summary, ranolazine at doses of 500 to 1,500 mg twice
aily significantly improves exercise performance and delays
r prevents the symptoms and ECG evidence of myocardial
schemia during exercise testing in patients with chronic
ngina. Consistent with ranolazine’s proposed metabolic
echanism, these effects occur with no (or only minimal)
hanges in BP and HR, and the tolerability of ranolazine
ppears acceptable. We conclude that ranolazine shows
romise as a new treatment for chronic angina.
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PPENDIX
or a list of the MARISA Publications Committee, the
ARISA Rest and Exercise ECG/MI/Ischemia Classifica-
ion Laboratory, Sponsor, and Investigators, please see the
pril 21, 2004, issue of JACC at http://www.cardiosource.
om/jacc.html.
